Tobie Escher, PhD

The Efficacy of Lumateperone 42 mg in the Treatment of Schizophrenia: A Pooled Analysis of Randomized Controlled Trials

Introduction: Lumateperone (lumateperone tosylate, ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that simultaneously modu...

Robert Davis , PhD;

Kimberly Vanover , PhD;

Andrew Satlin , MD;

Carol Tamminga , MD;

Sharon Mates , PhD;

Tobie Escher , PhD;

11/22/2019

Lumateperone 42 mg in an Open-Label Switch Study in Patients With Stable Schizophrenia: Results by Previous Antipsychotic

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. This analysis of open-...

Tobie Escher , PhD;

Eric Messamore ;

01/19/2023

Evaluation of Mania and Hypomania in Late-Phase Clinical Trials of Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis evaluated mania and hypomania across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-...

Tobie Escher , PhD;

10/26/2023